Incyte is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. JAKAFI (ruxolitinib) is Co.'s initial product approved by the U.S. Food and Drug Administration for the treatment of adults with intermediate or high-risk myelofibrosis, for the treatment of adults with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea, for the treatment of steroid-refractory acute graft-versus-host disease (GVHD) in adult and pediatric patients 12 years and older and for the treatment of chronic GVHD after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older. We show 56 historical shares outstanding datapoints in our INCY shares outstanding history coverage, used to compute INCY market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing Incyte market cap history over the course of time is important for investors
interested in comparing Incyte's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of Incyte versus a peer is one thing; comparing
Incyte market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like Incyte can fluctuate over the course of history.
With this page we aim to empower investors researching Incyte by allowing them to research the Incyte market cap history. |
Free INCY Email Alerts:
Video: The Importance of Market Cap
